Assignee
ARDELYX INC
US39 patents
Top patents by PatentIndex Score
US10272079B2Apr 30, 2019
NHE3-binding compounds and methods for inhibiting phosphate transport
ARDELYX INC5 citations83
US9408840B2Aug 9, 2016
Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorder
ARDELYX INC6 citations83
US8916569B2Dec 23, 2014
Compounds and methods for inhibiting phosphate transport
ARDELYX INC7 citations83
US8815910B2Aug 26, 2014
Compounds and methods for inhibiting phosphate transport
ARDELYX INC7 citations83
US8815908B2Aug 26, 2014
Compounds and methods for inhibiting phosphate transport
ARDELYX INC7 citations83
US8809339B2Aug 19, 2014
Compounds and methods for inhibiting phosphate transport
ARDELYX INC8 citations83
US11318129B2May 3, 2022
Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
ARDELYX INC1 citations72
US10543207B2Jan 28, 2020
Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
ARDELYX INC3 citations72
US10385024B2Aug 20, 2019
Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
ARDELYX INC3 citations72
US11242337B2Feb 8, 2022
Compounds useful for treating gastrointestinal tract disorders
ARDELYX INC3 citations71
US10968246B2Apr 6, 2021
Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
ARDELYX INC2 citations71
US10392413B2Aug 27, 2019
Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
ARDELYX INC3 citations71
US10376481B2Aug 13, 2019
Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
ARDELYX INC3 citations71
US11091482B2Aug 17, 2021
Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators
ARDELYX INC3 citations70
US10793568B2Oct 6, 2020
Hormone receptor modulators for treating metabolic conditions and disorders
ARDELYX INC4 citations70
US10940146B2Mar 9, 2021
NHE3-binding compounds and methods for inhibiting phosphate transport
ARDELYX INC1 citations62
US9006281B2Apr 14, 2015
Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
ARDELYX INC1 citations62
US8969377B2Mar 3, 2015
Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
ARDELYX INC3 citations62
US12016856B2Jun 25, 2024
Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
ARDELYX INC0 citations61
US11813304B2Nov 14, 2023
Compounds and methods for inhibiting phosphate transport
ARDELYX INC0 citations61
US12281103B2Apr 22, 2025
Compounds useful for treating gastrointestinal tract disorders
ARDELYX INC0 citations60
US12209088B2Jan 28, 2025
Hormone receptor modulators for treating metabolic conditions and disorders
ARDELYX INC0 citations60
US11718619B2Aug 8, 2023
Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators
ARDELYX INC0 citations60
US9433640B2Sep 6, 2016
Compositions and methods for treating hyperkalemia
ARDELYX INC2 citations60
US11753410B2Sep 12, 2023
Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorders
ARDELYX INC0 citations52
US9301951B2Apr 5, 2016
Compounds and methods for inhibiting phosphate transport
ARDELYX INC0 citations51
US9289430B2Mar 22, 2016
Compounds and methods for inhibiting phosphate transport
ARDELYX INC0 citations51
US9289429B2Mar 22, 2016
Compounds and methods for inhibiting phosphate transport
ARDELYX INC0 citations51
US9278102B2Mar 8, 2016
Compounds and methods for inhibiting phosphate transport
ARDELYX INC0 citations51
US12084472B2Sep 10, 2024
Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
ARDELYX INC0 citations50
US11858959B2Jan 2, 2024
Glycyrrhetinic acid derivatives for use in treating hyperkalemia
ARDELYX INC0 citations50
US11768319B2Sep 26, 2023
Glycyrrhetinic acid derivatives for treating hyperkalemia
ARDELYX INC0 citations50
US11147884B2Oct 19, 2021
Inhibitors of NHE-mediated antiport
ARDELYX INC0 citations50
US9919006B2Mar 20, 2018
Compositions and methods for treating hyperkalemia
ARDELYX INC0 citations49
US9867848B2Jan 16, 2018
Compositions and methods for treating hyperkalemia
ARDELYX INC0 citations49
US9655921B2May 23, 2017
Compositions and methods for treating hyperkalemia
ARDELYX INC0 citations49
US9549947B2Jan 24, 2017
Pharmaceutical compositions for treating hyperkalemia
ARDELYX INC0 citations49
US9545425B2Jan 17, 2017
Pharmaceutical compositions for treating hyperkalemia
ARDELYX INC0 citations49
US12539299B2Feb 3, 2026
Oral formulation of a therapeutic compound
ARDELYX INC0 citations42